Sign in
CompletedPhase 4

Vasopressin for Septic Shock Pragmatic Trial

Key facts

Who runs it
Intermountain Health Care, Inc.
Where
American Fork, Burley, Cedar City, Layton, Logan, Murray, Ogden, Park City, Provo, Riverton, Salt Lake City, Sandy City, and St. George, United StatesSee the 13 sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
3,959 people enrolled
Started
1 Feb 2024
Ended
6 Jun 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Vasopressin
  • Recommendation to use a lower initiation threshold for vasopressin
  • Recommendation to use a higher initiation threshold for vasopressin
Record updated
3 August 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Age ≥18 years
  • Admitted to a study hospital emergency department (ED) or inpatient care unit
  • Administration of vasopressor(s) for septic shock

Where in United States

  • American Fork HospitalAmerican Fork, United States
  • Cassia Regional HospitalBurley, United States
  • Cedar City HospitalCedar City, United States
  • Layton HospitalLayton, United States
  • Logan Regional HospitalLogan, United States
  • Intermountain Medical CenterMurray, United States
  • McKay-Dee HospitalOgden, United States
  • Park City HospitalPark City, United States
  • Utah Valley HospitalProvo, United States
  • Riverton HospitalRiverton, United States
  • LDS HospitalSalt Lake City, United States
  • Alta View HospitalSandy City, United States
  • St. George Regional HospitalSt. George, United States

About the trial

What the trial wants to find out

Life-threatening low blood pressure due to a serious infection is called "septic shock." Septic shock is treated with vasopressors, medications that raise blood pressure. Sometimes first-line vasopressors are inadequate, prompting addition of a second-line vasopressor called vasopressin. However, the threshold at which to start vasopressin remains unclear. This pragmatic, cluster-randomized, cluster-crossover trial will evaluate two different strategies for septic shock treatment commonly used in current practice, comparing a lower versus a higher threshold for adding vasopressin to first-line vasopressors.

The 2 groups in the trial

  • Septic shock treatment strategy involving a lower threshold for vasopressin initiationExisting treatment, for comparison

    Recommended strategy for treatment of septic shock includes initiation of fixed-dose IV vasopressin (1.8 units/hour) as a second-line vasopressor if the combined norepinephrine-equivalent dose of other vasopressors reaches ≥0.1 micrograms/kilogram/minute (mcg/kg/min). Use of the recommended treatment strategy (via entry of an order for threshold-based vasopressin initiation) or an alternative treatment strategy is at the discretion of patients' treating clinical team.

    Treatment: Vasopressin and Recommendation to use a lower initiation threshold for vasopressin

  • Septic shock treatment strategy involving a higher threshold for vasopressin initiationExisting treatment, for comparison

    Recommended strategy for treatment of septic shock includes initiation of fixed-dose IV vasopressin (1.8 units/hour) as a second-line vasopressor if the combined norepinephrine-equivalent dose of other vasopressors reaches ≥0.4 mcg/kg/min. Use of the recommended treatment strategy (via entry of an order for threshold-based vasopressin initiation) or an alternative treatment strategy is at the discretion of patients' treating clinical team.

    Treatment: Vasopressin and Recommendation to use a higher initiation threshold for vasopressin

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
3 August 2026